REPORT: Second quarter M&A sets 2014 up for a booming year
This article was originally published in Scrip
Executive Summary
The amount of pharmaceutical and life science mergers and acquisitions that closed in the second quarter did not exceed the first quarter of 2014, but the number and value of pending deals show that pharma and biotechnology dealmaking isn't about to slow down given the need for companies to expand their portfolios and global reach.